Search

About Extra Extra

Extra! Extra! is a blog devoted to current examples of investigative reporting, including in-depth projects, enterprise and breaking news with impact, use of public documents and Freedom of Information laws, use of data or computer-assisted reporting tools, and other examples of watchdog journalism from all media.

Email your story suggestions to extraextra@ire.org. Please include a working URL for the story; you may also include an optional synopsis of 100 words or less.

Extra Extra

Posted

Tagged

Willamette Week, the alt-weekly based in Portland, Ore., broke a story about Portland Mayor Sam Adams. After 16 months of reporting, Willamette Week compiled evidence that Adams had lied in 2007 about having sex with an 18-year-old legislative intern. In an interview last week, Adams again denied having sex with the young man but as WW prepared its story for publication on Monday, Adams confessed to the reporter Nigel Jaquiss.

Extra Extra

Posted

Tagged

Supporters from Barack Obama's home state held a celebration this week that was paid for, in part, by the same lobbying firms the president-elect banned from donating to his campaign and inaugural committee, Bloomberg's Jonathan D. Salant and Kate Andersen report. Seven firms that earned a total of at least $30 million in lobbying fees last year gave as much as $50,000 apiece for the Illinois gala. At least 28 state societies -- nonprofit groups that sponsor the balls -- have held pre-inaugural balls and events in Washington. Many relied on money from corporations and lobbyists to help make ...Read more ...

Extra Extra

Posted

Tagged

Internal Food and Drug Administration documents indicate that an FDA official overruled agency scientists and approved the sale of an imaging device for breast cancer after receiving a phone call from a Connecticut congressman. The legislator’s call and its effect on what is supposed to be a science-based approval process is only one of many of accusations in documents obtained by The New York Times regarding disputes within the Food and Drug Administration's office of device evaluation.
http://www.nytimes.com/2009/01/13/health/policy/13fda.html?ref=todayspaper